payor coverage
Medicare contractors want to rein in inappropriate use of genetics tests, but lab and pathologist groups worry that new coverage requirements may limit access.
The company beat expectations on the top and bottom lines in the second quarter, primarily driven by growth in clinical oncology testing, and upped its full-year revenue guidance.
As insurers drive down reimbursements, smaller labs are forced to accept payment rates similar to that of national outfits, but without the advantages of scale.
Guardant Health MRD Test Garners Coverage From Blue Cross, Blue Shield of Louisiana
The payor has initiated coverage of Guardant Reveal, a liquid biopsy test for detection and monitoring of residual cancer in patients with stage II and III colon cancer.
Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.